BeOne Medicines (NASDAQ:ONC) SVP Sells $959,760.00 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 2,666 shares of BeOne Medicines stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $360.00, for a total transaction of $959,760.00. Following the sale, the senior vice president owned 812 shares in the company, valued at approximately $292,320. This trade represents a 76.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, July 30th, Chan Henry Lee sold 1,044 shares of BeOne Medicines stock. The shares were sold at an average price of $323.69, for a total transaction of $337,932.36.
• On Wednesday, July 8th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The stock was sold at an average price of $302.46, for a total transaction of $200,833.44.
• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The stock was sold at an average price of $265.98, for a total transaction of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The stock was sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total value of $235,535.82.

BeOne Medicines Trading Down 2.4%

ONC stock opened at $347.48 on Friday. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $253.95 and a 1-year high of $385.22. The firm has a market cap of $38.13 billion, a P/E ratio of 61.18 and a beta of 0.49. The business’s 50 day moving average is $304.47 and its 200-day moving average is $309.51. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. The business had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on ONC. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday, July 17th. Wolfe Research restated an “outperform” rating and set a $370.00 price target on shares of BeOne Medicines in a research report on Monday, August 10th. Morgan Stanley restated an “overweight” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Finally, Wells Fargo & Company began coverage on BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BeOne Medicines currently has an average rating of “Buy” and a consensus price target of $402.14.

Hedge Funds Weigh In On BeOne Medicines

A number of large investors have recently modified their holdings of ONC. Capital International Investors increased its holdings in shares of BeOne Medicines by 1.3% in the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after purchasing an additional 67,808 shares in the last quarter. Siren L.L.C. lifted its holdings in BeOne Medicines by 1.4% during the 4th quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock worth $151,905,000 after buying an additional 7,010 shares in the last quarter. Morgan Stanley lifted its holdings in BeOne Medicines by 23.9% during the 4th quarter. Morgan Stanley now owns 437,661 shares of the company’s stock worth $132,966,000 after buying an additional 84,367 shares in the last quarter. Bank of America Corp DE boosted its position in BeOne Medicines by 7.0% in the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after buying an additional 26,441 shares during the last quarter. Finally, Candriam S.C.A. boosted its position in BeOne Medicines by 31.7% in the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after buying an additional 62,470 shares during the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.